文献速递胰腺与胆道疾病消化道肿瘤与早癌

胰腺STAT5激活促进KrasG12D诱导及炎症诱导的腺泡-导管化生与胰腺癌

Pancreatic STAT5 activation promotes KrasG12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer.
PubMed 文献 · Gut · 2024-10-07

该研究利用KCERT和KPC小鼠模型及条件性敲除STAT5或IL-22,结合胰腺炎诱导、原位移植和患者来源异种移植模型,发现STAT5在胰腺癌中高表达且高磷酸化,与预后不良相关;STAT5缺失可减少Kras突变及胰腺炎诱导的腺泡-导管化生和胰腺癌病变;IL-22信号通过促进STAT5磷酸化参与该过程。

要点

  • 胰腺STAT5激活是致癌KRAS信号的关键下游效应分子,对腺泡-导管化生起始和胰腺癌进展至关重要。
  • STAT5直接结合腺泡-导管化生介质HNF1β和HNF4α的启动子。
  • IL-22信号缺陷可减缓胰腺癌进展并消除STAT5激活。

核心结论

  • 胰腺STAT5激活是致癌KRAS信号的关键下游效应分子,对腺泡-导管化生起始和胰腺癌进展至关重要,提示其潜在治疗脆弱性。

研究设计与样本

  • 研究使用LSL-KrasG12D; Ptf1a-CreERT(KCERT)小鼠或LSL-KrasG12D; LSL-Trp53R172H; Pdx1-Cre(KPC)小鼠与STAT5条件性破坏或IL-22完全缺陷小鼠杂交。
  • 通过雨蛙素给药诱导小鼠胰腺炎。
  • 在原位移植和患者来源异种移植胰腺癌模型及KPC小鼠中研究STAT5药理学抑制对胰腺癌预防的作用。

主要发现

  • 人胰腺癌样本中STAT5表达和磷酸化高于对照样本,肿瘤细胞中STAT5高水平与较差预后相关。
  • 胰腺细胞中STAT5缺失大幅减少KRAS突变及胰腺炎衍生的腺泡-导管化生和胰腺癌病变。
  • 机制上,STAT5直接结合腺泡-导管化生介质肝细胞核因子(HNF)1β和HNF4α的启动子。
  • STAT5在胰腺癌进展中维持肿瘤细胞能量代谢起关键作用。
  • 慢性炎症诱导的IL-22信号增强KRAS突变介导的STAT5磷酸化;IL-22信号缺陷减缓胰腺癌进展并消除STAT5激活。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy because it is often diagnosed at a late-stage. Signal transducer and activator of transcription 5 (STAT5) is a transcription factor implicated in the progression of various cancer types. However, its role in KRAS-driven pancreatic tumourigenesis remains unclear. DESIGN: We performed studies with LSL-Kras G12D; Ptf1a-Cre ERT (KCERT) mice or LSL-KrasG12D; LSL-Trp53R172H ; Pdx1-Cre (KPC) mice crossed with conditional disruption of STAT5 or completed deficiency interleukin (IL)-22. Pancreatitis was induced in mice by administration of cerulein. Pharmacological inhibition of STAT5 on PDAC prevention was studied in the orthotopic transplantation and patient-derived xenografts PDAC model, and KPC mice. RESULTS: The expression and phosphorylation of STAT5 were higher in human PDAC samples than control samples and high levels of STAT5 in tumour cells were associated with a poorer prognosis. The loss of STAT5 in pancreatic cells substantially reduces the KRAS mutation and pancreatitis-derived acinar-to-ductal metaplasia (ADM) and PDAC lesions. Mechanistically, we discovered that STAT5 binds directly to the promoters of ADM mediators, hepatocyte nuclear factor (HNF) 1β and HNF4α. Furthermore, STAT5 plays a crucial role in maintaining energy metabolism in tumour cells during PDAC progression. IL-22 signalling induced by chronic inflammation enhances KRAS-mutant-mediated STAT5 phosphorylation. Deficiency of IL-22 signalling slowed the progression of PDAC and ablated STAT5 activation. CONCLUSION: Collectively, our findings identified pancreatic STAT5 activation as a key downstream effector of oncogenic KRAS signalling that is critical for ADM initiation and PDAC progression, highlighting its potential therapeutic vulnerability.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Lin Y, Pu S, Wang J, et al. Pancreatic STAT5 activation promotes KrasG12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer. Gut. 2024. PMID: 38955401. doi:10.1136/gutjnl-2024-332225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。